

























































SPECIALTY GRAND CHALLENGE ARTICLE
published: 20 November 2013
doi: 10.3389/fped.2013.00036
Specialty grand challenge – genetic disorders
JumanaY. Al-Aama*
Department of Genetic Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
*Correspondence: jalama@kau.edu.sa
Edited by:
Antonio Francesco Corno, University Sains Malaysia, Malaysia
Reviewed by:
Bruno Marino, University Sapienza of Rome, Italy
Keywords: genetic disorders, medical disorders, genome, geneticist, adolescence
Medical Genetics is going through rapid
growth with the help of evolving high
throughput technologies and collabora-
tive work across various scientific areas.
Human genome sequencing opened the
flood gate in identifying gene mutations
for hundreds of genetic diseases and the
genetic markers associated with complex
disease risk factors. This decade can be
considered as the golden age of medical
genetics, which raises the biggest chal-
lenges for scientists from various fields,
such as: Genetics, “Omics,” Bioinformatics,
stem cell biology, and system biology, etc.
to work together.
Human genome sequencing created
massive amount of data and in turn led
the way in identifying millions of common
variants (SNPs) in the population (1). High
throughput technologies using microar-
rays to screen millions of SNPs made it easy
for scientists to carry out more than 1000
genome wide disease association (GWAS)
studies and identify many disease associ-
ated markers (2). Whole exome sequenc-
ing (WES) and whole genome sequencing
(WGS) are helping us to identify muta-
tions in rare diseases (3). For example,
whole exome analysis was exploited to its
full, with many publications in high impact
journals. Between 2010 and 2013, we have
witnessed more rapid growth in identi-
fying gene mutations in genetic diseases,
especially rare diseases (4). These high
throughput technologies brought together
scientists across the globe to identify fam-
ilies with rare diseases and unravel previ-
ously unknown genetic secrets. The next
stage of this era is moving toward appli-
cation of these technologies in newborn
screening and for diagnostics. This step
faces multiple challenges in many areas
before being introduced into the healthcare
system (5, 6).
Newer technologies are being developed
to make the analysis faster and more reli-
able. Scientists are caught in the web of
catch up with the new technology to be
the first ones to cash in on their beneficial
effect. It is a never ending game that stimu-
lates scientists and tries to address yet big-
ger challenges in this field. Success is slowly
gaining momentum with this approach,
but more collaboration will make the ulti-
mate goal of patient care through science a
reality.
High throughput data generation is
accelerating so fast, that newer bioin-
formatics tools are needed to deal with
large data. The informatics world is tak-
ing up the challenge. Hundreds of new
bioinformatics tools are being developed
to the ever changing high through put
technologies. Close interaction of bioin-
formatics scientists with the bench sci-
entists will provide the families and
the clinicians with better options for
patient care. Handling of whole exome
and genome sequencing data requires
a complex informatics pipeline and
many groups are introducing tools which
will tackle the large scale data gener-
ated by such high throughput technolo-
gies (7).
Every one of the gene mutation or SNP
association solves one problem, but raises
10 questions in diagnosis, functional role,
and treatment, etc. Diagnosis of the fam-
ily at risk and development of accurate
tests are the first step into the personalized
patient care approach. It needs to be pri-
oritized by the scientists. High throughput
technologies in ’omics are being increas-
ingly utilized to integrate genetics with
’omics data to understand the biologi-
cal functions and pathways, etc. Func-
tional understanding of the mutated genes
or associated SNPs and their role in the
human body is increasingly addressed by
in vivo and in vitro methods (8). Geneti-
cists are increasingly collaborating with sci-
entists with different biological skills to
unravel the functions of genes and how to
modify (activate or inhibit) them to control
or to treat patients.
Treating individuals by replacing defec-
tive genes is the ultimate challenge. Hope-
fully, this will be successfully addressed by
the evolving technologies and newer dis-
coveries in various scientific fields. Rapid
publication of such important discoveries
will disseminate the results faster to scien-
tists around the world. High cost of health
care across the globe, demands from fam-
ilies of affected patients and government
organizations are pushing the pharmaceu-
tical industry to make better medicines
as well as personalized medicine for bet-
ter patient care. Personalized Medicine and
Pharmacogenetics are emerging fields. Suc-
cess with personalized medicine is seen
in many cancer treatments. Treatment of
diseases is being explored using the func-
tional effect of mutations, for example,
successful CFTR activator treatment for a
small group of cystic fibrosis patients with
specific mutations (9). Functional under-
standing of causative genes will open the
door for rare disease treatments (10).
Frontiers journal encourages scientists
to submit their exciting work to address
challenging questions raised in the field of
Medical Genetics. Frontiers journals will
join with the scientists to disseminate the
new discoveries all over the world as early
as possible for the benefit of patients.
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